X4 is focused on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases.
Our first-in-class, oral, small molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. A number of PIs are attributed to the improper trafficking of immune cells related to the CXCR4 receptor and its ligand CXCL12.
X4 is led by a team with experience in research, development and commercialization of therapies to treat rare diseases, with its Headquarters located in Cambridge, MA and its Research and Development Site located in Vienna, Austria.
13.03.2019: X4 Pharmaceuticals Completes Merger with Arsanis.